Novel Biomarkers as Potential Predictors of Decompensated Advanced Chronic Heart Failure-Single Center Study

Area of Science:

• Cardiology
• Biomarker Discovery
• Internal Medicine

Background:

• Heart failure (HF) presents significant diagnostic and therapeutic challenges.
• Current biomarkers for HF decompensation lack specificity, often elevated in other conditions.
• Distinguishing acute decompensated HF from compensated HF requires improved diagnostic tools.

Purpose of the Study:

• To evaluate the predictive potential of four novel cardiovascular biomarkers: suPAR, H-FABP, VCAM-1, and GDF-15.
• To assess these biomarkers for detecting cardiac decompensation in HF patients.
• To differentiate between acute decompensated HF and compensated HF.

Main Methods:

• Prospective enrollment of 146 heart failure patients.
• Serum biomarker concentrations analyzed using Enzyme Linked Immunosorbent Assay (ELISA).
• Correlation of biomarker levels with clinical and biochemical parameters; assessment of predictive value for cardiac decompensation.

Main Results:

• Significantly elevated levels of suPAR, H-FABP, VCAM-1, and GDF-15 observed in acute decompensated HF vs. compensated HF.
• suPAR (1.6-fold), H-FABP (2.2-fold), VCAM-1 (1.6-fold), and GDF-15 (1.7-fold) showed significant increases (p < 0.0001 to p=0.0458).
• Univariate logistic regression confirmed significant associations between biomarker concentrations and cardiac decompensation risk.

Conclusions:

• Novel biomarkers suPAR, GDF-15, VCAM-1, and H-FABP show potential for aiding therapeutic decisions in HF.
• These biomarkers may help identify patients with suspected cardiac decompensation.
• Further research is needed to establish reliable, sensitive, and specific tools for early detection, considering factors like renal function.